Study details
Enrolling now
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis
Eli Lilly and Company
NCT IDNCT07186101ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
252
Study length
about 3.4 years
Ages
18–80
Locations
41 sites in AZ, CA, CO +16
What this study is about
Researchers are testing whether LY4268989, given with mirikizumab, is more effective than mirikizumab alone for adults with moderately to severely active ulcerative colitis. The trial will last about 118 weeks and involve approximately 252 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take LY4268989
- 2.Take LY4268989 Placebo
- 3.Take Mirikizumab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
mirikizumab
Body systems
Gastroenterology